Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary

Takano, Masashi; Goto, Tomoko; Kato, Masafumi; Sasaki, Naoki; Miyamoto, Morikazu; Furuya, Kenichi
June 2013
International Journal of Clinical Oncology;Jun2013, Vol. 18 Issue 3, p556
Academic Journal
No abstract available.


Related Articles

  • Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. Liontos, Michalis; Lykka, Maria; Meletios-Athanasios; Dimopoulos; Bamias, Aristotle // OncoTargets & Therapy;2014, Vol. 7, p1837 

    Angiogenesis has been implicated in ovarian cancer pathogenesis. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been incorporated in ovarian cancer treatment in combination with chemotherapy both in a frontline setting and in disease recurrence....

  • Targeted Tumor Therapies at a Glance. Fuchs, H.; Bachran, C. // Current Drug Targets;Feb2009, Vol. 10 Issue 2, p89 

    Conventional tumor therapy is usually based on surgery, radiation and chemotherapy. Treatment with chemotherapeutics is often impeded by dose-limiting toxicities. Therefore, medical scientists sought for tools to improve chemotherapy by directly coupling targeting molecules to cytotoxic...

  • Combination Approach: the Future of the War Against Cancer. Chen, Lan; Malhotra, Anshoo // Cell Biochemistry & Biophysics;Jul2015, Vol. 72 Issue 3, p637 

    Cancer remains one of the major health problems worldwide and is responsible for one in eight deaths. The worldwide research against cancer as well as genome wide association studies was successful in indentifying the loci associated with cancer but still a substantial amount of casualty remains...

  • Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors. Confino, Hila; Hochman, Ilan; Efrati, Margalit; Schmidt, Michael; Umansky, Viktor; Kelson, Itzhak; Keisari, Yona // Cancer Immunology, Immunotherapy;Feb2015, Vol. 64 Issue 2, p191 

    Introduction: The current systemic anti-metastatic treatment is chemotherapy. Chemotherapy reacts mostly against replicating cells, which makes this therapy not specific. Moreover, resting cancer cells will not be destroyed. A better alternative is an engagement of the host immune system to...

  • Corosolic acid enhances the antitumor effects of chemotherapy on epithelial ovarian cancer by inhibiting signal transducer and activator of transcription 3 signaling. YUKIO FUJIWARA; KIYOMI TAKAISHI; JUNKO NAKAO; TSUYOSHI IKEDA; HIDETAKA KATABUCHI; MOTOHIRO TAKEYA; YOSHIHIRO KOMOHARA // Oncology Letters;2013, Vol. 6 Issue 6, p1619 

    Resistance to chemotherapy poses a serious problem for the treatment of advanced epithelial ovarian cancer patients. The mechanisms of chemoresistance are complex and studies have implicated signal transducer and activator of transcription 3 (STAT3) signaling in the chemoresistance of cancer...

  • Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Yang, Yeong-In; Lee, Kyung-Tae; Park, Hee-Juhn; Kim, Tae Jin; Choi, Youn Seok; Shih, Ie-Ming; Choi, Jung-Hye // Carcinogenesis;Dec2012, Vol. 33 Issue 12, p2488 

    Paclitaxel (Taxol) is currently used as the front-line chemotherapeutic agent for several cancers including ovarian carcinoma; however, the drug frequently induces drug resistance through multiple mechanisms. The new strategy of using natural compounds in combination therapies is highly...

  • Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells. Kunos, Charles A.; Stefan, Tammy; Jacobberger, James W. // Frontiers in Oncology;Sep2013, Vol. 3, p1 

    Background: Up to 40% of women with ovarian cancer have short disease-free intervals due to molecular mechanisms of chemotherapy resistance. New therapeutic strategies are sought. Ovarian cancers are sensitive to radiochemotherapy. The taxane cabazitaxel (XRP6258, Jevtana) promotes tubulin...

  • Clinical development directions in oncolytic viral therapy. Eager, R M; Nemunaitis, J // Cancer Gene Therapy;May2011, Vol. 18 Issue 5, p305 

    Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicative-competent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested...

  • Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? Gallo, Chiara; Buonerba, Carlo; Lorenzo, Giuseppe; Romeo, Valeria; Placido, Sabino; Marinelli, Alfredo // Journal of Neuro-Oncology;Nov2010, Vol. 100 Issue 2, p311 

    Glioblastoma multiforme (GBM), the highest grade malignant glioma, is associated with a grim prognosis-median overall survival is in the range 12-15 months, despite optimum treatment. Surgery to the maximum possible extent, external beam radiotherapy, and systemic temozolomide chemotherapy are...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics